Marzeptacog alfa (activated)

DB15278InvestigationalProtein Based Therapies

Marzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia).

Mechanism: Pharmacologically active on Coagulation factor VII
Curator reviewed
Also known as: PF-05280602

Resolves to

Compound

UNIIJ5LT149M79CAS1600492-21-4

Targets

P08709F7

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Marzeptacog alfa (activated), and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account